RAD51C, RAD51D Mutations, High-Level BRCA1 Promotor Methylation Predictive Of Response To Rucaparib In Patients With Recurrent Ovarian Cancer, Trial Results Show

May 05, 2021

OncLive (5/4, Rosa) reports, “RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib (Rubraca) in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination defic...